URGN - UroGen Pharma Ltd Stock Price, Fair Value and News

$10.64-0.07 (-0.65%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

URGN Price Action

Last 7 days

-6.3%

Last 30 days

-7.1%

Last 90 days

-21.4%

Trailing 12 Months

-29.4%

URGN RSI Chart

URGN Valuation

Market Cap

449.0M

Price/Earnings (Trailing)

-3.89

Price/Sales (Trailing)

5.02

EV/EBITDA

-4.02

Price/Free Cashflow

-4.66

URGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

URGN Fundamentals

URGN Revenue

Revenue (TTM)

89.4M

Rev. Growth (Yr)

20.87%

Rev. Growth (Qtr)

15.36%

URGN Earnings

Earnings (TTM)

-115.4M

Earnings Growth (Yr)

-8.2%

Earnings Growth (Qtr)

29.13%

URGN Profitability

Operating Margin

90.27%

EBT Margin

-124.59%

Return on Equity

-452.2%

Return on Assets

-38.21%

Free Cashflow Yield

-21.47%

URGN Investor Care

Shares Dilution (1Y)

36.72%

URGN Alerts

Point72 Asset Management, L.P. reported owning 3.6% of URGN [2024-11-14]
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	84.3M	85.0M	89.4M	0
2023	68.0M	72.5M	77.3M	82.7M
2022	54.1M	57.7M	62.4M	64.4M
2021	19.3M	31.9M	39.8M	48.0M
2020	7.2M	8.8M	10.3M	11.8M
2019	0	2.7M	4.2M	5.7M
2018	8.6M	9.0M	1.5M	1.1M
2017	15.2M	12.8M	10.5M	8.2M
2016	0	0	0	17.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

CEO	Ms. Elizabeth A. Barrett
WEBSITE	urogen.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	193

UroGen Pharma Ltd Frequently Asked Questions

What is the ticker symbol for UroGen Pharma Ltd? What does URGN stand for in stocks?

URGN is the stock ticker symbol of UroGen Pharma Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of UroGen Pharma Ltd (URGN)?

As of Fri Dec 20 2024, market cap of UroGen Pharma Ltd is 449 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of URGN stock?

You can check URGN's fair value in chart for subscribers.

Is UroGen Pharma Ltd a good stock to buy?

The fair value guage provides a quick view whether URGN is over valued or under valued. Whether UroGen Pharma Ltd is cheap or expensive depends on the assumptions which impact UroGen Pharma Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for URGN.

What is UroGen Pharma Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, URGN's PE ratio (Price to Earnings) is -3.89 and Price to Sales (PS) ratio is 5.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. URGN PE ratio will change depending on the future growth rate expectations of investors.